首页> 外文期刊>Journal of biomedical materials research, Part A >Stiffness-controlled three-dimensional collagen scaffolds for differentiation of human Wharton's jelly mesenchymal stem cells into cardiac progenitor cells
【24h】

Stiffness-controlled three-dimensional collagen scaffolds for differentiation of human Wharton's jelly mesenchymal stem cells into cardiac progenitor cells

机译:刚度可控的三维胶原蛋白支架,可将人沃顿氏胶体间充质干细胞分化为心脏祖细胞

获取原文
获取原文并翻译 | 示例
           

摘要

Stem cell-based regenerative therapy has emerged as a promising treatment for myocardial infarction. The aim of this study is to develop stiffness-controlled collagen scaffolds to allow proliferation and differentiation of mesenchymal stem cell (MSCs) into cardiac progenitor cells. In this study transforming growth factor 2 (TGF-2), was used to induce stem cell differentiation into cardiac lineage cells. Collagen scaffolds were cross-linked with cross-linkers, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), and N-Hydroxysuccinimide (NHS). The results showed that collagen scaffolds cross-linked with 25/50 and 50/50 of EDC mM/NHS mM cross-linkers exhibited little difference in shape and size, the scaffold cross-linked with 50/50 of cross-linkers demonstrated better interconnectivity and higher Young's modulus (31.8 kPa) than the other (15.4 kPa). SEM observation showed that MSCs could grow inside the scaffolds and interact with collagen scaffolds. Furthermore, greater viability and cardiac lineage differentiation were achieved in MSCs cultured on stiffer scaffolds. The results suggest that three-dimensional type I collagen scaffolds with suitable cross-linking to adjust for stiffness can affect MSC fate and direct the differentiation of MSCs into cardiac progenitor cells with/without TGF-2. These stiffness-controlled collagen scaffolds hold great potential as carriers for delivering MSCs differentiated cardiac progenitor cells into infracted hearts. (c) 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 2234-2242, 2016.
机译:基于干细胞的再生疗法已经成为心肌梗塞的有前途的治疗方法。这项研究的目的是开发刚度控制的胶原蛋白支架,以允许间充质干细胞(MSCs)增殖和分化为心脏祖细胞。在这项研究中,转化生长因子2(TGF-2)用于诱导干细胞分化为心脏谱系细胞。胶原蛋白支架与交联剂,1-乙基-3-(3-二甲基氨基丙基)碳二亚胺(EDC)和N-羟基琥珀酰亚胺(NHS)交联。结果表明,与25/50和50/50的EDC mM / NHS mM交联剂交联的胶原蛋白支架在形状和大小上几乎没有差异,与50/50交联剂交联的支架显示出更好的互连性杨氏模量(31.8 kPa)高于其他(15.4 kPa)。 SEM观察表明,MSCs可以在支架内部生长并与胶原支架相互作用。此外,在较硬的支架上培养的MSC中获得了更大的生存力和心脏谱系分化。结果表明,具有适当交联以调节硬度的三维I型胶原蛋白支架可以影响MSC的命运,并指导MSCs分化为有/无TGF-2的心脏祖细胞。这些刚度可控的胶原蛋白支架具有巨大的潜力,可作为将MSCs分化的心脏祖细胞输送至心脏的载体。 (c)2016 Wiley Periodicals,Inc.J Biomed Mater Res Part A:104A:2234-2242,2016。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号